Total androgen blockade for metastatic cancer of the prostate.
作者信息
Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey E W, Trachtenberg J, Venner P M
机构信息
Service of Urology, Notre-Dame Hospital, University of Montreal, Québec, Canada.
出版信息
Am J Clin Oncol. 1988;11 Suppl 2:S187-90. doi: 10.1097/00000421-198801102-00043.
Abstract
This randomized, double-blind study comparing orchiectomy plus placebo to orchiectomy plus a nonsteroid antiandrogen (Anandron) shows that total androgen blockade for metastatic cancer of the prostate provides a significantly better early objective response when compared to castration alone. This response, however, is less apparent at 18 months. The study also suggests a longer survival for the patients with total androgen blockade.
摘要
相似文献
1
Total androgen blockade for metastatic cancer of the prostate.
Am J Clin Oncol. 1988;11 Suppl 2:S187-90. doi: 10.1097/00000421-198801102-00043.
2
Anandron (RU 23908) associated with orchiectomy in stage D prostate cancer. Preliminary results of a randomized, double-blind study.
Am J Clin Oncol. 1988;11 Suppl 2:S191-6. doi: 10.1097/00000421-198801102-00044.
3
Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
Cancer. 1993 Dec 15;72(12 Suppl):3874-7. doi: 10.1002/1097-0142(19931215)72:12+<3874::aid-cncr2820721722>3.0.co;2-#.
4
5
6
Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
Cancer. 1993 Dec 15;72(12 Suppl):3886-7. doi: 10.1002/1097-0142(19931215)72:12+<3886::aid-cncr2820721725>3.0.co;2-k.
7
Combination of Anandron with orchiectomy in treatment of metastatic prostate cancer. Results of a double-blind study.
Urology. 1991;37(2 Suppl):25-9. doi: 10.1016/0090-4295(91)80098-r.
8
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
Urology. 2001 Apr;57(4):727-32. doi: 10.1016/s0090-4295(00)01086-4.
9
Total androgen ablation: Canadian experience.
Urol Clin North Am. 1991 Feb;18(1):75-82.
10
Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
J Urol. 1997 Jul;158(1):160-3. doi: 10.1097/00005392-199707000-00051.
引用本文的文献
1
Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.
Curr Oncol. 2006 Jun;13(3):81-93. doi: 10.3747/co.v13i3.85.
2
Maximal androgen blockade for advanced prostate cancer.
Cochrane Database Syst Rev. 2000;1999(2):CD001526. doi: 10.1002/14651858.CD001526.
3
Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.
Drugs. 1990 Mar;39(3):399-437. doi: 10.2165/00003495-199039030-00007.
4
Flutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in advanced prostatic cancer.
Drugs Aging. 1991 Mar;1(2):104-15. doi: 10.2165/00002512-199101020-00003.
Zotero 插件